Wächterlymphknotenbiopsie - Aktuelle Studienkonzepte

Zusammenfassung

Die Wächterlymphknotenbiopsie wird weltweit als grundsätzliche Methode des nodalen Stagings bei Melanom angesehen. Inzwischen wird allgemein akzeptiert, dass ein positiver Wächterlymphknotenbefund der wichtigste prognostische Faktor für das Gesamtüberleben darstellt. Die entscheidende Frage dieser Methode ist jedoch, ob das diagnostische Verfahren Wächterlymphknotenbiopsie gefolgt ist von einem therapeutischen Nutzen für die Patienten. Diese Frage wird zur Zeit in verschiedenen Studienkonzepten der USA und Deutschlands überprüft.

Abstract

Sentinel lymph node biopsy is regarded world-wide as the principal staging method for melanoma. Meanwhile it is commonly accepted that a positive sentinel lymph node is the most important prognostic factor for overall survival. The crucial question for this method, however, is whether the diagnostic procedure sentinel lymph node biopsy is followed by a therapeutical benefit for the patients. These questions are at present answered in randomized multicentre clinical trials in the USA and Germany.

Literatur

• 1 Abramson L R. Sentinel-lymph-node biopsy.  N Engl J Med. 1999;  340 317-319
• 2 Bachter D, Balda B R, Vogt H, Buchels H. Die „sentinel” Lymphnodektomie mittels Szintillationsdetektor. Eine neue Strategie in der Behandlung maligner Melanome.  Hautarzt. 1996;  47 754-758
• 3 Balch C M, Buzaid A C, Atkins M B, Cascinelli N, Coit D G, Fleming I D, Houghton A Jr, Kirkwood J M, Mihm M F, Morton D L, Reintgen D, Ross M I, Sober A, Soong S J, Thompson J A, Thompson J F, Gershenwald J E, McMasters K M. A new American Joint Committee on Cancer staging systems for cutaneous melanoma.  Cancer. 2000;  88 1484-1491
• 4 Blaheta H J, Ellwanger U, Schittek B, Sotlar K, Maczey E, Breuninger H, Thelen M H, Bueltmann B, Rassner G, Gaber C. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma.  J Invest Dermatol. 2000;  114 637-642
• 5 Bland K I. Microstaging of sentinel lymph nodes.  Ann Surg Oncol. 1999;  6 15-16
• 6 Bognar J, Nagy P, Kadar E, Bajtai A, Mayer A, Daroczy J, Jakab F. The current surgical treatment of primary malignant melanoma of the skin.  Acta Chir Hung. 1997;  36 37-38
• 7 Bongers V, Rinkes H MB, Barneveld P C, Caninga van Dijk M R, van Rijk P P, van Vloten W A. Towards quality assurance of the sentinel node procedure in malignant melanoma patients: a single institution evaluation and a European survey.  Eur J Nucl Med. 1999;  26 84-90
• 8 Bostick P J, Morton D L, Turner R R, Huynh K T, Wang H J, Elashoff R, Essner R, Hoon D S. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients.  J Clin Oncol. 1999;  17 3238-3244
• 9 Brady M S, Coit D G. Lymphatic mapping in the management of the patient with cutaneous melanoma.  Cancer J. 1997;  10 87-93
• 10 Brady M S, Coit D G. Sentinel lymph node evaluation in melanoma.  Arch Dermatol. 1997;  133 1014-1020
• 11 Brobei A, Kamath D, Cruse C W, Rapaport D P, Wells K E, Shons A R, Messina J L, Glass L F, Berman C G, Puleo C A, Reintgen D S. The clinical relevance of sentinel lymph nodes identified with radiolymphoscintigraphy.  J Fla Med Assoc. 1997;  84 157-160
• 12 Carlson G W, Murray D R, Greenlee R, Alazraki N, Fry-Spray C, Poole R, Blais M, Hestley A, Vansant J. Management of malignant melanoma of the head and neck using dynamic lymphoscintigraphy and gamma probe-guided sentinel lymph node biopsy.  Arch Otolaryngol Head Neck Surg. 2000;  126 433-437
• 13 Cascinelli N, Morabito A, Saninami M. et al . Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomized trial - WHO Melanoma Programme.  Lancet. 1998;  14 793-796
• 14 Emilia J C, Lawrence W Jr. Sentinel lymph node biopsy in malignant melanoma: the standard of care?.  J Surg Oncol. 1997;  65 153-154
• 15 Gennari R, Stoldt H S, Bartolomei M, Zurrida S, Testori A, Mazzarol G, Paganelli G, Veronesi U. Sentinel node localisation: A new prospective in the treatment of nodal melanoma metastases.  Int J Oncol. 1999;  15 25-32
• 16 Gershenwald J E, Thompson W, Mansfield P F, Lee J E, Colome M I, Tseng C H, Lee J J, Balch C M, Reintgen D S, Ross M I. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients.  J Clin Oncol. 1999;  17 976-983
• 17 Koller J, Rettenbach L. Sentinel-Lymph-Node Biopsie.  Hautarzt. 2000;  51 47-56
• 18 McNeil C. Sentinel node biopsy: studies should bring needed data.  J Natl Cancer Inst. 1998;  90 728-730
• 19 Morton D L, Chan A D. Current status of intraoperative lymphatic mapping for early stage melanoma.  J Am Coll Surg. 1999;  189 213-223
• 20 Morton D L, Chan A D. The concept of sentinel node localization: how it started.  Sem Nucl Med. 2000;  30 4-10
• 21 Morton D L, Thompson J F, Essner R, Elashoff R, Stern S l, Nieweg O E, Roses D F, Karakousis C P, Mozzillo N, Reintgen D, Wang H J, Glass E C, Cochran A J. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group.  Ann Surg. 1999;  230 453-465
• 22 Morton D L, Wen D R, Cochran A J. Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy.  Surg Oncol Clin North Am. 1992;  1 247-259
• 23 Reintgen D S, Brobeil A. Lymphatic mapping and selective lymphadenectomy as an alternativ to elective lymph node dissection in patients with malignant melanoma.  Hematol Oncol Clin North Am. 1998;  12 807-821
• 24 Retsas S. Sentinel-lymph-node biopsy.  N Engl J Med. 1999;  340 318-319